Increased production of prostacyclin after injury to the microvasculature in uraemic patients by Slazus, W.
VOl81 21 MAR 1992 315
SAMJ
Increased production ofprostacyclin after injury to the
microvasculature in uraemic patients
w. SLAZUS
Summary A recently described tnethod to evaluate the pri-
tnary haetnostatic tnechanistn under in vivo con-
ditions was utilised to investigate throtnboxane
fu (TXA.z) and prostacyclin (pGL) production by
platelets and vascular endothelial cells, respec-
tively, in patients with severe chronic renal
failure. Unlike sotne previous studies, a decrease
in TXA.z production by uraetnic platelets could not
be detnonstrated. PGL - produced by tnicrovas-
cular endothelial cells after a standardised injury
- was, however, 59% higher in patients than con-
trols (P < 0,05). An increased local level of this
potent platelet inhibitory eicosanoid could play an
itnportant role in the bleeding tendency exhibited
in chronic renal failure.
S Air Med J 1992; 81: 315·317.
I t is well known that uraemia is associated with ableeding tendency. The incidence of dangerousbleeding episodes has decreased since the introduc-
tion of dialysis, but is still a problem for patients needing
major surgical procedures or diagnostic biopsies of, for
mstance, the kidney or liver. I
A prolonged bleeding time is still the best, although
it is not infallible, indicator of a clinical bleeding ten-
dency.' Various aetiological factors have been proposed
to explain this defect, e.g. a low packed-cell volume
(PCV);"" depressed in vitro platelet aggregation;'
decreased thromboxane A, (TXA,) production by
platelets;' increased prostacyclin (PGH production by
endothelial cells;"· abnormalities of von Willebrand
factor"1O and parathyroid hormone;" and abnormal
platelet surface carbohydrates." Conflicting results are
regularly published""l3·l3 and the true pathogenesis of
this defect of primary haemostasis is still unresolved.
A new experimental approach to the evaluation of
primary haemostasis has recently been published. I 6-I'
Blood collected from curs made for measurement of
bleeding time, a standardised injury of the microvascula-
ture, is used for the measurement of different mediators
operative in haemostasis, e.g. thromboxane B, (TXB,)
.- as an end-product of platelet cyclo-oxygenase activity
- and 6-keto-prostaglandin FIn (6KPGF) - as an indi-
cation of vascular endothelial synthesis of PGI,.
In the present study in vivo production of TXA,
by platelets and PG}, by vascular endothelium was
examined in patients with severe chronic renal failure
and compared with normal controls.
Patients and methods
The protocol was approved by the Ethical Comminee of
the Medical Faculty, University of Stellenbosch, and
informed consent was obtained from all patients.
Ten patients, 8 men and 2 women, with severe
chronic renal failure (serum creatinine value over
600 llIDol/l or receiving regular haemodialysis) were
examined. Patients on haemodialysis were examined
immediately before a dialysis session. No diabetics,
patients with nephrotic syndrome or patients receiving
drugs that could influence prostaglandin metabolism
were included in the study. No patient received recom-
binant human erythropoietin. Age-comparable healthy
volunteers, 7 men and 3 women, on no drugs that could
influence prostaglandin metabolism, were used as con-
trols for bleeding time, TXB, and 6KPGF determina-
tions.
The bleeding times were determined according to
the standardised method of Mielke et al.,'o using a dis-
posable apparatus (Simplate n, General Diagnostics,
Morris Plains, NJ, USA). Duplicate horizontal incisions,
5 mm in length and 1 mm deep, were made on the
lateral volar aspect of the forearm. All bleeding times
were measured by the same investigator.
Blood from bleeding-time curs was collected, as
recently described,""· with some modifications. The
blood was sucked up in heparinised capillary tubes
containing 60 MM indomethacin (Sigma Chemical Co.,
Poole, UK), immediately blown out into plastic
Eppendorf tubes, centrifuged at 4 000 g for 10 minutes
in a modified Beckman Microfuge, drav,'l1 off and frozen
at -80°C until analysis.
Blood was also drawn from an antecubital vein or the
dialysis fistula in the absence of heparin. For coagulation
tests blood was drawn into 3,8% sodium cirrate
(9: I v/v), centrifuged to obtain platelet-poor plasma and
tested immediately.
TXB, and 6KPGF were measured by commercially
available radio-immunoassay kits (Amersham Inter-
national, Amersham, Bucks, UK). Some 6KPGF
measurements were done with half the volumes of speci-
men, specific antibody, marker and second antibody as
recommended by the manufacturers because of the
small volume. The validity of the modification was con-
firmed by finding no significant difference between
results using the recommended and modified methodo-
logy (41,3 ± 10,6 pg/ml and 43,5 ± 18,2 pg/m! respec-
tively; N = 13).
Platelet count, packed cell volume, serum creatinine
level, prothrombin time ratio (PTR), activated partial
thromboplastin time (APTT) and clonable fibrinogen
were determined by routine methods.
Statistics. A non-parametric method (Mann-
\Vhimey U-test) was applied to compare TXB, and
6KPGF values between patients and controls and P <
0,05 was regarded as statistically significant. All results
are expressed as mean ± SD.
Results
Haematological values (Table I)
The PTR (normal range 1,0 - 1,3), APTT (normal
range 25 - 40 s) and plasma fibrinogen (normal range
2 - 4 g/I) were within normal limits in all patients. The
blood platelet count was normal in 9 patients and
decreased to 55 x 10'/1 in L
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Bleeding tUne (Table I)
Six patients had a prolonged skin bleeding time (normal
range 2 - 9 min) of over 12 minutes, while it was at the
upper limit of the normal range (8 - 9 minutes) in the
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6KPGF
(pg/ml)
TXB2
(pg/ml)
TABLE I.
Formation of TXB, and 6KPGF in blood obtained from template bleeding-time incisions and patient bleeding times
haemoglobin levels and platelet counts '
Patients Controls
Haemoglobin Platelet count Bleeding time TXB, 6KPGF
(g/I) (x 109/1) (min) (pg/ml) (pg/mI)
Subject
No.
1
2
3
4
5
6
7
8
9
10
Mean
1 010,9
679,3
407,1
645,4
607,6
1758,1
654,1
919,3
988,7
846,9
851,7±371,0
53,8
71,7
81,9
86,5
84,6
45,2
25,2
37,1
42,7
64,1
59,3< ± 21,7
38,9 283 8 1 232,0 23,1
71 141 > 12 373,1 16,2
48 55 > 12 684,4 20,4
98 394 > 12 1 148,3 21,4
69 491 > 12 479,6 27,4
77 251 7 636,9 54,9
78 233 > 12 477,6 35,2
64 207 >12 555,7 51,7
102 268 9 443,1 67,1
93 258 7 652,9 55,1
73,9 ± 20,5 258 ± 121 668,4 ± 292,9 37,3 ± 18,3
'p< 0.05.
other 4 patients. All the controls had bleeding times that
were within normal limits.
TXB2 and 6KPGF in blood from bleed-
ing time cuts (Table I)
In the controls 668,4 ± 292,9 pgiml TXB, and 37,3 ±
18,3 pgiml 6KPGF was measured in blood collected
over the whole duration of the bleeding time. The
amount ofTXB, measured in uraemic patients (851,7 ±
371,0 pgiml) did not differ significantly from that of the
controls (P > 0,05). The production of 6KPGF was,
however, increased by 59% in uraemic patients (59,3 ±
21,7 pgiml) compared with controls and this difference
was statistically significant (P < 0,05). The TXB,;
6KPGF ratio did not differ significantly between the
patient (17,4) and the control (23,5) group. There was
no significant correlation between haemoglobin levels,
bleeding times, platelet counts and either TXB, or
6KPGF levels. Because of the small number of patients
in the study, this cannot be regarded as absolute proof
of non-correlation.
Discussion
Prostaglandin metabolites of the cyclo-oxygenase path-
way play a very important role in the aggregation of
platelets. TXA, is strongly stimulatory"'" and PGI,
strongly inhibitory" to platelet aggregation. Both have
short half-lives in vivo and the stable breakdown pro-
ducts TXB, and 6KPGF are measured in vitro as an
indication of in ·vivo production.
It has recently been shown that the measurement of
different mediators of haemostasis in blood collected
from bleeding-time cuts is an excellent method for in
vivo evaluation of the primary haemostatic mecha-
nism. 17•ls These measurements are indicative of events at
the level of the primary haemostatic mechanism and,
unlike measurements of TXB, and 6KPGF in venous
blood or urine, are not an indication of production in
the whole vascular system and other sources, e.g. the
kidneys.
Results of in vitro experiments, e.g. the determination
of PGI, production by isolated vascular tissue of
uraemic patients, should be verified, if possible, by in
vivo methods, e.g. as used in the present study. The in
vivo method is also sensitive to abnormal cyclo-oxy-
genase activity, as has been shown by measurement of
TXB, after treatment with low dose aspirin. IS
The results of the present study are an indication
that in vivo production of TXfu by uraemic platelets is
not reduced in comparison with normal controls. In
patients on maintenance haemodialysis specimens were
obtained immediately before the next dialysis and
platelet activation during dialysis could thus not account
for the failure to demonstrate decreased production of
TXB,. The presence of a functional cyclo-oxygenase
defect, one of the proposed mechanisms of the uraemic
bleeding tendency, could thus not be confirmed by this
in '(n'vo evaluation.
The production of PGI, by injured vascular endothe-
lial cells of uraemic patients is, however, significantly
increased. The above findings confirm the results of
Kyrle et al. 9 who used a similar method of investigation.
The lower TXB:J6KPGF ratio in the patients, in spite of
higher levels of TXB, than the controls, also suggests
that the increased PGI, levels are more important than
the increase in production ofTXA!.
The cause of the increased production of prosta-
cyclin has not been determined. It has been shown
that normal platelet-poor plasma contains a factor that
causes release of prostacyclin from vascular endothelial
cells in culture. Platelet-poor plasma from uraemic
patients causes an increased rate of synthesis and release
of prosracyclin in the same system.'· The precise nature
of this factor, which is present in normal and uraemic
plasma, has not been determined. Prostacyclin is a
potent vasodilator and inhibitor of platelet aggregation
and the findings of this study could thus explain the
defective platelet-endothelial interaction and consequent
prolonged bleeding time of uraemic patients. A decreas-
ing effect of treatment modalities known to improve the
uraemic bleeding diathesis, e.g. haemodialysis, on
prostacyclin production by vascular endothelial cells in
vivo could help to substantiate this.
The clinical application of these results is still uncer-
tain. Selective pharmacological inhibition of vascular
endothelial cell cyclo-oxygenase or prostacyclin syn-
thetase would be the theoretical solution to the problem,
but such an agent is not yet available. It has been shown
in in vitro experiments that vitamin KI can inhibit
prostacyclin production by bovine vascular endothelial
cells." As far as could be ascertained, this substance has
not been clinically used for the treatment of the uraemic
bleeding tendency. This widely available and inexpen-
sive form of treatment, that could correct one of the
basic pathophysiological defects of haemostasis in the
uraemic patient, should be evaluated in a clinical trial.
The author wishes to thank the Renal Unit, Tygerberg
Hospital, for permission to study their notes and also
Mrs E. Fourie and Mrs H. Cloete for expert technical assis-
rance.
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Summary Rectal induction of anaesthesia is a useful Illethod
but is not widely used in South Africa. We studied
the onset of action and side-effects of 1% Illetho-
hexitone adIllinistered rectally in a dose of 20
Illglkg to 110 preschool children. Ninety-one per
cent were adequately sedated for inhalation induc-
tion by Illask within 10 minutes, and all by 15
Illinutes, of drug administration. There was no
evidence of significant cardiovascular or respira-
tory depression and only minor complications
such as faecal soiling (11,8%) and hiccough (3,6%)
were noted.
The technique has been favourably received by
parents, surgeons and nursing staff and has now
becoIlle routine practice.
S AIr MedJ 1992; 81: 317-318.
~e smooth induction of anaesthesia in preschoolchildren presents a specific challenge to thegeneral anaesthetist in a busy peripheral or day
hospital. Oral premedication, favoured by many because
it provides anxiolysis and facilitates the induction of
anaesthesia, may have serious unwanted side-effects. In
addition, appropriate timing is essential for it to be
effective.
Rectal induction is an alternative nOt commonly used
or taught in South Africa. It has been described as prob-
Accep(ed 19 Aug 1991.
Reprin( reqUe5rs (0: Or A. T. Bosenberg, Dep( of Anaesthesia, University of Na(al
Medical School, PO Box 17039, Congella, 4013 RSA.
ably the least disturbing method of inducing anaesthe-
sia, since it involves neither a painful injection nor swal-
lowing of suspicious-looking potions. 1
We therefore investigated the use of 1% methohexi-
tone for rectal induction of anaesthesia for both day
surgery and inpatient surgery in a peripheral hospital
setting.
Methods
Preschool children, ASA physical status I and II, pre-
senting for elective surgery during a 6-month period
were studied prospectively. Both outpatients and in-
patients were involved. Children under the age of 6
months or those in whom a 'difficult airway' was sus-
pected were excluded from the study.
During the routine pre-operative visit the procedure
was explained to both parent and child and the age, sex
and weight were nOted. No additional pharmacological
premedicant was prescribed.
At the time of surgery the child was accompanied to
the operating room by a parent or caring adult. In the
operating room the child was placed in the lateral posi-
tion while the parent talked to and comforted the child
as required.
A freshly prepared 1% methohexitone solution in a
dose of 20 mglkg to a maximum of 500 mg was injected
rectally via a soft red rubber catheter Gacques) using a
10 ml or 20 ml plastic syringe. The catheter was lubri-
cated with KY jelly and was inserted to a depth of 2 cm.
The time of injection was noted. Following the injec-
tion, the bunocks were taped together in an anempt to
prevent any loss of medication.
At 10 and 15 minutes after the injection the level of
consciousness of the child was assessed. 'Asleep' was
defined as no response to the application of a face-mask,
'sedated' as response to the mask or the introduction of
halothane, and 'awake' as resistance to the face-mask.
